JP2009516653A5 - - Google Patents

Download PDF

Info

Publication number
JP2009516653A5
JP2009516653A5 JP2008540168A JP2008540168A JP2009516653A5 JP 2009516653 A5 JP2009516653 A5 JP 2009516653A5 JP 2008540168 A JP2008540168 A JP 2008540168A JP 2008540168 A JP2008540168 A JP 2008540168A JP 2009516653 A5 JP2009516653 A5 JP 2009516653A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
solvate
hydrate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008540168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009516653A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/043513 external-priority patent/WO2007058850A2/en
Publication of JP2009516653A publication Critical patent/JP2009516653A/ja
Publication of JP2009516653A5 publication Critical patent/JP2009516653A5/ja
Pending legal-status Critical Current

Links

JP2008540168A 2005-11-10 2006-11-09 Ａｋｔ活性の阻害剤 Pending JP2009516653A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73595505P 2005-11-10 2005-11-10
US77228906P 2006-02-10 2006-02-10
US82692806P 2006-09-26 2006-09-26
PCT/US2006/043513 WO2007058850A2 (en) 2005-11-10 2006-11-09 Inhibitors of akt activity

Publications (2)

Publication Number Publication Date
JP2009516653A JP2009516653A (ja) 2009-04-23
JP2009516653A5 true JP2009516653A5 (enExample) 2009-12-17

Family

ID=38049129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008540168A Pending JP2009516653A (ja) 2005-11-10 2006-11-09 Ａｋｔ活性の阻害剤

Country Status (16)

Country Link
US (1) US20100056523A1 (enExample)
EP (1) EP1948188A4 (enExample)
JP (1) JP2009516653A (enExample)
KR (1) KR20080067646A (enExample)
AP (1) AP2008004442A0 (enExample)
AR (1) AR056786A1 (enExample)
AU (1) AU2006315805A1 (enExample)
BR (1) BRPI0618309A2 (enExample)
CA (1) CA2629429A1 (enExample)
EA (1) EA200801301A1 (enExample)
EC (1) ECSP088425A (enExample)
IL (1) IL190968A0 (enExample)
MA (1) MA29935B1 (enExample)
NO (1) NO20082414L (enExample)
TW (1) TW200736260A (enExample)
WO (1) WO2007058850A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948185A4 (en) * 2005-11-10 2010-04-21 Glaxosmithkline Llc INHIBITORS OF AKT ACTIVITY
EP3358354B1 (en) 2008-01-18 2020-07-15 President and Fellows of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CA2723852A1 (en) * 2008-05-16 2009-11-19 Cellzome Ag Methods for the identification of parp interacting molecules and for the purification of parp proteins
US20110086834A1 (en) * 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
JP5702293B2 (ja) 2008-11-10 2015-04-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
BRPI0924084B1 (pt) 2008-12-19 2021-12-21 Vertex Pharmaceuticals Incorporated Derivados de pirazina e composição farmacêutica que os compreende
WO2011143422A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of atr kinase
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
AU2011253025A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011163527A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
SG10201505724SA (en) * 2010-07-23 2015-09-29 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
KR20130133051A (ko) 2011-03-16 2013-12-05 에프. 호프만-라 로슈 아게 6,5-헤테로사이클릭 프로파길릭 알콜 화합물 및 이의 용도
WO2012138938A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
MX2014003796A (es) 2011-09-30 2015-01-16 Vertex Pharma Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
IN2014CN02501A (enExample) 2011-09-30 2015-06-26 Vertex Pharma
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
EP2776422A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US20140044802A1 (en) 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SMT202000713T1 (it) 2012-12-07 2021-03-15 Vertex Pharma Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
ES2909438T3 (es) 2013-06-26 2022-05-06 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Enantiómero (S) de mepacina como inhibidor de paracaspasa (MALT1) para tratar cáncer
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) * 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
CN107074863B (zh) 2014-06-05 2019-12-03 沃泰克斯药物股份有限公司 Atr激酶抑制剂的制备方法及其不同的固体形式
PL3157566T3 (pl) 2014-06-17 2019-10-31 Vertex Pharma Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
MX371151B (es) 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
BR112017007704B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V Derivados de pirazolopirimidina como inibidores de nik, seu uso e composição farmacêutica que os compreende
US9981962B2 (en) 2014-10-23 2018-05-29 Janssen Pharmaceutica Nv Pyrazole derivatives as NIK inhibitors
ES2718557T3 (es) 2014-10-23 2019-07-02 Janssen Pharmaceutica Nv Nuevos compuestos como inhibidores de nik
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
WO2020078865A1 (en) 2018-10-16 2020-04-23 F. Hoffmann-La Roche Ag Use of akt inhibitors in ophthalmology
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
CN119278041A (zh) 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
CN120051280A (zh) 2022-10-17 2025-05-27 阿斯利康(瑞典)有限公司 用于治疗癌症的serd的组合
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic

Similar Documents

Publication Publication Date Title
Minniti et al. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents
JP2010528026A5 (enExample)
JP6436205B2 (ja) キノリン誘導体
JP2009514870A5 (enExample)
JP2010518110A5 (enExample)
US20050256157A1 (en) Combination therapy with CHK1 inhibitors
JP2011126896A5 (enExample)
JP4934432B2 (ja) キナゾリン誘導体およびキナゾリン誘導体の治療への使用
JP2014097929A5 (enExample)
CN104817497B (zh) 一种炔代喹啉衍生物及其制备方法和用途
RU2009113615A (ru) Ингибитор киназы
JP2003507342A (ja) 結腸ポリープおよび直腸結腸癌の処置または抑制のためのｎｓａｉｄおよびｅｇｆｒキナーゼインヒビターを含有する組成物
CA2890699A1 (en) Combination therapy
BRPI0620058A2 (pt) combinação farmacêutica compreendendo compostos inibidores da ligação da proteìna smac a proteìnas inibidoras de apoptose, e um taxano, bem como uso da mesma
JP2012512158A5 (enExample)
Li et al. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate
EP1682123A1 (en) Cancer treatment method
JP2011500805A5 (enExample)
CN1511036A (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
JP2005516895A (ja) 腫瘍の治療のための２−アシルインドールの使用
JP2012526767A5 (enExample)
CN103965119A (zh) 含有锌结合基的不可逆egfr酪氨酸激酶抑制剂
JP2006517951A5 (enExample)
Pattanayak et al. Azetidine‐Based Small‐Molecule Targeted Anticancer Agents: Developments in the Last Decade (2015–2024)
US12162876B2 (en) Indazole kinase inhibitor and use thereof